Viewing Study NCT01696734


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-26 @ 1:08 AM
Study NCT ID: NCT01696734
Status: RECRUITING
Last Update Posted: 2025-12-15
First Post: 2012-09-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Domperidone in Treating Patients With Gastrointestinal Disorders
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Overview

Official Title: Treatment Protocol for the Compassionate Use of Domperidone
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.
Detailed Description: PRIMARY OBJECTIVES:

I. To provide treatment with domperidone to patients \>= 16 years of age where, according to the investigators' judgment, a prokinetic effect is needed for the relief of gastrointestinal (GI) motility disorders.

OUTLINE:

Patients receive domperidone orally (PO) thrice daily (TID) or four times daily (QID). Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for at least 30 days.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
NCI-2012-02093 REGISTRY CTRP (Clinical Trial Reporting Program) View
2012-0261 OTHER M D Anderson Cancer Center View